Nuala Meyer of the Perelman School of Medicine said she was surprised by the FDA’s approval of remdesivir for patients hospitalized with COVID-19. "We always expect the FDA to base decisions on data and we do get concerned when we see decision-making that we can't find the data to support," she said.